RedHill Biopharma (RDHL) Enterprise Value (2016 - 2025)
Historic Enterprise Value for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to -$4.6 million.
- RedHill Biopharma's Enterprise Value rose 5286.21% to -$4.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$4.6 million, marking a year-over-year increase of 5286.21%. This contributed to the annual value of -$7.0 million for FY2024, which is 6624.66% up from last year.
- RedHill Biopharma's Enterprise Value amounted to -$4.6 million in Q2 2025, which was up 5286.21% from -$6.0 million recorded in Q4 2024.
- In the past 5 years, RedHill Biopharma's Enterprise Value registered a high of -$4.6 million during Q2 2025, and its lowest value of -$76.0 million during Q1 2021.
- Moreover, its 5-year median value for Enterprise Value was -$22.9 million (2021), whereas its average is -$26.4 million.
- As far as peak fluctuations go, RedHill Biopharma's Enterprise Value plummeted by 11568.86% in 2021, and later surged by 7572.02% in 2023.
- Quarter analysis of 5 years shows RedHill Biopharma's Enterprise Value stood at -$29.5 million in 2021, then rose by 23.35% to -$22.6 million in 2022, then increased by 8.33% to -$20.7 million in 2023, then skyrocketed by 70.84% to -$6.0 million in 2024, then increased by 23.35% to -$4.6 million in 2025.
- Its Enterprise Value was -$4.6 million in Q2 2025, compared to -$6.0 million in Q4 2024 and -$9.8 million in Q2 2024.